{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+1st+Cycle", "query": { "intervention": "Placebo - 1st Cycle" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 458, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+1st+Cycle&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T04:16:57.058Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07556718", "title": "Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Quiescent Crohn's Disease (CD)" ], "interventions": [ { "name": "Amitriptyline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2026-06-03", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07556718" }, { "nct_id": "NCT00759317", "title": "Physiologic Monitoring of Antidepressant Treatment Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depression" ], "interventions": [ { "name": "venlafaxine (Effexor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2001-06", "completion_date": "2002-09", "has_results": false, "last_update_posted_date": "2014-07-03", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00759317" }, { "nct_id": "NCT02144610", "title": "Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Critical Limb Ischemia" ], "interventions": [ { "name": "HGF Plasmid (AMG0001)", "type": "BIOLOGICAL" }, { "name": "Matching Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AnGes USA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 46, "start_date": "2014-11-12", "completion_date": "2016-11-28", "has_results": true, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 28, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02144610" }, { "nct_id": "NCT01663727", "title": "Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Bevacizumab [Avastin]", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 481, "start_date": "2012-08-27", "completion_date": "2017-11-21", "has_results": true, "last_update_posted_date": "2019-01-22", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663727" }, { "nct_id": "NCT02734862", "title": "CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Candidemia", "Mycoses", "Fungal Infection", "Fungemia", "Invasive Candidiasis" ], "interventions": [ { "name": "CD101", "type": "DRUG" }, { "name": "Caspofungin", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" }, { "name": "oral placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 207, "start_date": "2016-07-26", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Davis, California • Miami, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Davis", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02734862" }, { "nct_id": "NCT00345605", "title": "Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Argininosuccinic Aciduria", "Amino Acid Metabolism, Inborn Errors", "Urea Cycle Disorders" ], "interventions": [ { "name": "Sodium Phenylbutyrate", "type": "DRUG" }, { "name": "Arginine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brendan Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 12, "start_date": "2008-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345605" }, { "nct_id": "NCT03086369", "title": "A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Olaratumab", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2017-06-22", "completion_date": "2021-06-17", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 32, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 26 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086369" }, { "nct_id": "NCT01337154", "title": "First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tamibarotene", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytRx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2011-04", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 3, "location_summary": "Rancho Mirage, California • Kansas City, Kansas • Hackensack, New Jersey", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01337154" }, { "nct_id": "NCT01301183", "title": "Effects of Anorexia Nervosa on Peak Bone Mass", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anorexia Nervosa" ], "interventions": [ { "name": "RhIGF-1 with transdermal 17-beta estradiol", "type": "DRUG" }, { "name": "Placebo and transdermal 17-beta estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": "22 Years", "sex": "FEMALE", "summary": "14 Years to 22 Years · Female only" }, "enrollment_count": 75, "start_date": "2011-02", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2021-07-13", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01301183" }, { "nct_id": "NCT04622007", "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tomivosertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2021-06-02", "completion_date": "2024-12-09", "has_results": false, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-09-09T04:16:57.058Z", "location_count": 131, "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04622007" } ] }